Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar(Center for Drug Evaluation and Research), Gϋnter von Minckwitz(German Breast group), Michael Untch(Helios Kliniken), José Baselga(Novartis (Switzerland)), David Cameron(Corewell Health), Peter A. Fasching(Universitätsklinikum Erlangen), Jens‐Uwe Blohmer(Sankt Gertrauden Krankenhaus), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmyung Paik(Yonsei University), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Tatiana M. Prowell(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Leen Slaets(European Organisation for Research and Treatment of Cancer), Norman Wolmark(NSABP Foundation), Hervé Bonnefoi, Luca Gianni(Fondazione Michelangelo), Pinuccia Valagussa(Fondazione Michelangelo), Charles M. Perou(University of North Carolina at Chapel Hill), Charles E. Geyer(Magee-Womens Hospital), Sandra M. Swain(Georgetown University), Semiglazov Vf(Institute of Oncology NN Petrov), Jonas Bergh(Karolinska Institutet), Holger Eidtmann, D. Lawrence Wickerham(University of Pittsburgh), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), Eleftherios P. Mamounas(Orlando Health), Martine Piccart(Université Libre de Bruxelles), Sibylle Loibl(Goethe University Frankfurt), Bernd Gerber(Universitäts Frauenklinik), Nina Ditsch(University of Augsburg), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Keyur Mehta(German Breast group), Joseph P. Costantino(NSABP Foundation), Priya Rastogi(UPMC Hillman Cancer Center), Lijun Zhang(Dalian Medical University), W. Eiermann(Ludwig-Maximilians-Universität München)
Cited by 4,694
Related Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
|New England Journal of Medicine|2005|5.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k